Year in Review for Drug and Device Advertising and Promotion: Lessons Learned From 2022 FDA Enforcement Letters and Other Key Developments

Please join our experienced panel for a review of key takeaways from the FDA’s 2022 drug and device advertising and promotion enforcement letters and a discussion of other noteworthy developments relevant to drug and medical device marketing.  Panelists will discuss:

• Lessons learned from 2022 drug and device advertising and promotion enforcement and trends related to social media, patient videos and online interviews, misleading efficacy claims, presentation of risk information, and pre-approval promotion
• Other relevant developments, including recent device-related Lanham Act litigation, FTC activities related to endorsements and consumer reviews, and OPDP research initiatives
• Predictions for what may be expected in 2023

For questions, contact Twilah Robinson at trobinson@kslaw.com.

CLE

King & Spalding is an accredited provider of CLE credit in California, Georgia, Illinois, New York and Texas. We can issue reciprocal credit for attorneys licensed in Connecticut, Florida and New Jersey. We will apply for credit in Colorado, North Carolina and Virginia (subject to MCLE Board approval). For jurisdictions not listed, attendees are provided with a Universal Certificate of Attendance. New York licensed attorneys: Transitional/Appropriate for newly admitted and experienced attorneys. Financial aid is available for qualifying lawyers. For CLE-related questions, please contact Gisel Arias at garias@kslaw.com. King & Spalding, 1180 Peachtree Street NE, Atlanta, GA 30309. CA Provider #10947.